相关实验视频
Updated: Jun 28, 2025

07:14
Acupuncture in a Rat Model of Asthma
Published on: August 25, 2020
6.0K
电针通过激活过敏性喘大鼠的体感交感通路来减少呼吸道炎症
Hongli Ma1, Xiaowen Liu, Huamei Cai
1Department of Anesthesia, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100029, China.
Chinese medical journal
|April 11, 2024
概括
在BL13针点的电针 (EA) 激活体感同情路径,以改善呼吸道炎症和喘中的粘液分泌. 这种机制涉及甲基胺释放和T细胞上的β-2上腺素受体激活,减少关键的炎症性细胞因子.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 电针 (EA) 在呼吸系统疾病中显示出有效性,但其肺部保护机制尚不清楚.
- 本研究调查了EA在BL13针点 (Feishu) 的神经解剖学基础,以改善过敏性喘.
研究的目的:
- 阐明EA-BL13在过敏性喘小鼠模型中发挥治疗作用的神经解剖学途径.
- 确定EA诱导的呼吸道炎症和粘液产生减少背后的分子机制.
主要方法:
- 过敏性喘是使用卵蛋白 (OVA) 敏感化和挑战诱导的.
- 用ELISA测量了介质素 (IL) - 4和IL-5水平;通过组织学评估了炎症和粘液分泌.
- 使用免疫光和实时PCR分别分析了神经元激活 (c-fos) 和上腺素受体mRNA表达.
主要成果:
- EA-BL13显著降低了气道炎症和粘液分泌 (P <0.001).
- 治疗激活了体感同情路径,由脊髓中侧核 (IML) 传递到肺部的信号.
- 交感神经的激活导致了儿科胺的释放,激活T细胞上的β2上腺素受体 (β2AR),并通过cAMP/PKA通路减少IL-4/IL-5 (P <0.01).
结论:
- 治疗EA-BL13提供了一个神经解剖学解释的机制来改善过敏性喘.
- 这些发现支持EA-BL13作为过敏性喘和相关的炎症性呼吸道疾病的可行治疗选择.
相关概念视频
Asthma: Pathogenesis and Management
391
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
391
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
284
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
284
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists
292
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
292

